Skip to content

Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers

Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers: a Double-blind, Randomized,Controlled Clinical Trial.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01954901
Enrollment
2
Registered
2013-10-07
Start date
2013-10-31
Completion date
2015-08-31
Last updated
2020-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wagner Grade 2 Lower Extremity Ulcers

Brief summary

The purpose of this proposed DoD study is to determine if hyperbaric oxygen therapy (HBOT) plus standard wound care is more effective than standard wound care alone in the rate of healing and prevention of major amputation (metatarsal and proximal) in Wagner grade 2 diabetic lower extremity ulcers.

Interventions

DEVICEHyperbaric oxygen therapy

Sponsors

David Grant U.S. Air Force Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age equal to or greater than 18. 2. Type 1 or 2 diabetes mellitus. 3. Wagner Grade 2 wound for at least 4 weeks. A diagnosis of a Wagner Grade 2 wound necessitates a persistent wound of 4 weeks (5). 4. DoD Beneficiary.

Exclusion criteria

1. Impending/urgent amputation due to ongoing or exacerbated infection. 2. Severe depression. 3. Claustrophobia. 4. Seizure disorder. 5. Uncontrolled asthma/severe COPD with pCO2 \> 45 mmHg on arterial blood gas. 6. Grade 4 congestive heart failure. 7. Unstable angina. 8. Chronic/acute otitis media/sinusitis. 9. Major tympanic membrane trauma. 10. Prior chemotherapy with Bleomycin and evidence of deterioration in diffusing capacity after a single hyperbaric oxygen exposure. 11. Candidates for vascular surgery/angioplasty/stenting or patients with major large vessel disease. These patients could have peripheral vascular disease of such severity that hyperbaric treatment would not improve their condition. 12. Vascular surgery/angioplasty within the last 3 months. This exclusion controls for improvements to a patients vasculature and perfusion that occur within 1-2 months after vascular surgery/angioplasty. This will ensure that any perfusion changes to the patient's diabetic wound ulcer area recorded during the study are a result of hyperbaric therapy instead of recent vascular procedures. 13. Women who are breast feeding or of childbearing potential. 14. Dementia or mental disability rendering the potential subject incapable of following instructions or consenting to treatment.

Design outcomes

Primary

MeasureTime frame
Changes in wound size - wounds measured by length, width and depth14 months
Number of wounds healed14 months
Number of major and minor amputationsThree Years after initiation of study

Secondary

MeasureTime frame
Peri-wound TCOM values14 months
Recurrence of ulceration14 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026